Harry Clifford
Entrepreneur-in-Residence, Health Tech
Harry is an Entrepreneur-in-Residence at Oxford Science Enterprises – he’s on a mission to find and co-found a new HealthTech business. His focus is on the intersection of digital biology and AI.
He joined in 2025 with more than a decade of experience in biotechnology, machine learning, and venture-building. Most recently, he led digital biology product development in genomics and AI-driven drug discovery at NVIDIA.
Previously, Harry co-founded Cambridge Cancer Genomics, a Y-Combinator-backed startup that exited to Dante Labs in 2021.
Harry holds an MSci in Human Genetics from the University of Nottingham, a DPhil in Next Generation Sequencing technologies from the University of Oxford, and completed postdoctoral research in cancer bioinformatics at the University of Cambridge.
WORK WITH US
Oxford researchers & innovators
Want your research to have real-world impact?
We partner with researchers and innovators across Oxford, Harwell and Culham to explore commercial potential, co-create ventures and build companies.
Investors
Interested in becoming an OSE shareholder?
We’ve raised over £850m from global investors keen to access Oxford’s diverse, world-leading science. Our shareholders don’t just back OSE – many also co-invest alongside us.
Co-investors
Looking to invest in Oxford’s most exciting spinouts?
We partner with specialist global investors to fund and scale our companies – from pre-seed to growth. Together, OSE and our co-investors have invested more than £3bn.